PSMA PET/CT
More than 3.1 million American men are currently living with prostate cancer. An improved PET/CT scan could also mean an improved prostate cancer treatment plan, which is why ADR now offers PSMA PET/CT scans using Pylarify®.
What is a PSMA PET/CT?
A PSMA PET/CT is a new imaging technique used to locate cancerous lesions. PSMA stands for Prostate-Specific Membrane Antigen which is essentially a protein that is found mainly on prostate cancer cells. The radioactive tracer is injected and attaches to PSMA proteins. When a whole body scan is performed, the concentrated PSMA tracer is detected and pinpoints the tumors for more effective treatment.
What is Pylarify?
PYLARIFY® is a diagnostic imaging agent used in conjunction with PET/CT scans to find tumors in the prostate, lymph nodes, bones, and other organs. PYLARIFY® uses a radioactive tracer called fluorine-18 that attaches to prostate-specific membrane antigen (PSMA), a protein found on the surface of most prostate cancer cells. By targeting PSMA, PYLARIFY® can give your doctor a clearer image and information on the location and the extent of the cancer.
Who is a candidate for a PSMA PET/CT?
Those with suspected metastasis who are candidates for initial definitive therapy and those with suspected recurrence based on elevated PSA levels are best suited for this exam.
